Updates in the Treatment of Advanced Renal Cell Carcinoma

An overview of advanced Renal Cell Carcinoma (aRCC), including its prevalence, patient presentation, classification, and treatment criteria.

Discussion centered around available first-line combination options for patients with aRCC as well as factors influencing treatment choice.

Panelists analyze the 4-year follow-up results of the CLEAR study, covering study design, efficacy, safety, and clinical implications.

The panel engages in a discussion on lenvatinib dosing in clinical practice, addressing dose reductions, their impact on treatment effectiveness, and real-world tolerability.

Expert oncologists share experiences and insights on key treatment protocols for patients with aRCC, including perspectives from community oncologists.

Panelists provide insight on ongoing studies evaluating doublet combinations in frontline advanced RCC.

Ongoing studies assessing triplet regimens in frontline advanced RCC and their influence on treatment decisions are discussed, including efficacy outcomes.

The panel explores unmet needs in aRCC treatment and shares expectations for changes and advances in the landscape in the near future.